TP53 and cancer: In patients with p53 wild-type cancer, highΔ40p53 expression was significantly associated with improved recurrence-free (33.4 vs 19.6 months, P=0.029), but not with overall survival (43.1 vs 33.6 months, P=0.139; Table 3; Figure 2C and D).